CARDINAL is a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, pharmacokinetics (PK), and efficacy of TERN-701 in patients with relapsed/refractory CML with or ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

Background: Acute myeloid leukemia (AML) is a hematologic tumor with poor prognosis and significant clinical heterogeneity. By integrating transcriptomic data, single-cell RNA sequencing data and ...

Chronic myeloid (or myelogenous) leukaemia (CML), also known as chronic granulocytic leukaemia, is a cancer of the white blood cells. It is characterized by the increased and unregulated growth of ...

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm characterized by CSF3R mutations. Here, we report the first case of a CNL patient positive for a de-novo germline CSF3R T618I ...

Nearly one in five people in the UK are believed to suffer from chronic inflammation – but there are ways to reduce it There’s an important distinction to be made between acute inflammation ...

In some countries, including the US, Scemblix is also approved in patients with Ph+ CML-CP with the T315I mutation. Scemblix is being studied across multiple treatment lines for Ph+ CML-CP, both as a ...

The data included results from all patients with KMT2A rearrangement (KMT2Ar) or NPM1 mutation (NPM1m) who had received at least one dose of enzomenib and who had not received a menin inhibitor ...

Researchers reported that while the third-generation BCR-ABL1 TKIs had previously been shown to be safe and effective among patients with CML who were either resistant or intolerant to two prior TKIs ...

The immediate pressing clinical issues in the CP-CML setting include patients with T315I mutations, which account for 15% of imatinib resistance mutations. At present, the therapeutic options for ...

“In summary, all the mutations that emerged in this study with the treatment [of] asciminib have ... “Asciminib’s favorable risk-benefit profile compared with all IS-TKIs, imatinib, and ...